The Medicines Company Is Up 161% Year to Date, but Here's a Better Way to Play the Drugmaker's Success
Investors should go to the source.
Alnylam Pharmaceuticals
ALNY
ALNY
$78.97
$1.33
1.7%
BATS BZX Real Time Price as of October 11, 2019, 4:00 p.m. EDT
View Interactive ALNY Charts
A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.
News & Analysis: Alnylam Pharmaceuticals
The Fool has written over 200 articles on Alnylam Pharmaceuticals.
3 Biotech Stocks That Could Soar This Week
Investors better get ready for a busy week ahead.
Alnylam Adds on Sales, Looks to Pipeline for Further Growth
The biotech could go from one to four marketed drugs in a little over a year.
Alnylam Pharmaceuticals Inc (ALNY) Q2 2019 Earnings Call Transcript
ALNY earnings call for the period ending June 30, 2019.
Alnylam Pharmaceuticals Continues Onpattro Launch With More to Come
Additional drug approvals and launches are on the way.
Can Alnylam Pharmaceuticals Stock Start Climbing Again?
Investors are starting to wonder if there's anything that can lift this stock higher.
Alnylam Pharmaceuticals Inc (ALNY) Q1 2019 Earnings Call Transcript
ALNY earnings call for the period ending March 31, 2019.
Is Alnylam Pharmaceuticals a Buy Now?
Everything's falling into place for the pioneer of RNA interference.
2 Biotechs With Big Dates in April
Here's what you need to know about two biotechs that will present trial results that could send their stock prices soaring -- or plummeting.
Alnylam Pharmaceuticals Is Launched and Ready for More
The biotech has launched its first drug, Onpattro, but don't forget about its pipeline of drugs to come.
